xpro1595
·Code: XPro1595
xpro1595: 2 clinical trials tracked.
xpro1595 evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about xpro1595, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Clinical Trial Registry Records (2)
An Open Label Extension of XPro1595 in Patients With Alzheimer's Disease That Have Completed a Phase 1 or Phase 2 Study With XPro1595
Primary endpoint: Number of participants who experience adverse events and serious adverse events
Interventionalopen11 targetStarted 2023-02Completion 2024-074 sites · AustraliaInmune Bio, Inc.
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
Primary endpoint: Change in Early and Mild Alzheimer's Cognitive Composite (EMACC)
InterventionalRandomizedquadruple207 enrolledStarted 2022-02Completion 2025-0541 sites · Australia, Canada, Czechia, France…Inmune Bio, Inc.